Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 10;11(5):393.
doi: 10.3390/jpm11050393.

Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment

Francesca De Felice  1 , Daniela Musio  1 , Vincenzo Tombolini  1
Affiliations
Review

Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment

Francesca De Felice et al. J Pers Med. .

Abstract

In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research.

Keywords: HPV; check-point inhibitors; chemoradiotherapy; definitive treatment; head neck cancer; immunotherapy; outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram describing the data collection process following the PRISMA convention.
See this image and copyright information in PMC

References

    1. Shield K.D., Ferlay J., Jemal A., Sankaranarayanan R., Chaturvedi A.K., Bray F., Soerjomataram I. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J. Clin. 2016;67:51–64. doi: 10.3322/caac.21384. - DOI - PubMed
    1. National Comprehensive Cancer Network Guidelines in Oncology Head and Neck Cancers Version 1. [(accessed on 27 December 2020)];2020 Available online: http://www.nccn.org/
    1. De Felice F., Polimeni A., Valentini V., Brugnoletti O., Cassoni A., Greco A., De Vincentiis M., Tombolini V. Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review. Neoplasia. 2018;20:227–232. doi: 10.1016/j.neo.2018.01.002. - DOI - PMC - PubMed
    1. Velcheti V., Schalper K. Basic Overview of Current Immunotherapy Approaches in Cancer. Am. Soc. Clin. Oncol. Educ. Book. 2016;35:298–308. doi: 10.1200/EDBK_156572. - DOI - PubMed
    1. De Felice F., Marchetti C., Palaia I., Ostuni R., Muzii L., Tombolini V., Benedetti Panici P. Immune check-point in cervical cancer. Crit. Rev. Oncol. Hematol. 2018;129:40–43. doi: 10.1016/j.critrevonc.2018.06.006. - DOI - PubMed

LinkOut - more resources